Comparison of arterial and interstitial glucose levels in critical state
| Autor: | Petr Kopecky, Štěpán Svačina, Jaroslav Lindner, Martin Haluzik, Bosanská L, R. Dolezalova, Jan Bláha, Jan Jiskra, Kotrlíková E, J Kremen |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Nutrition and Dietetics Statin business.industry Cholesterol medicine.drug_class Endocrinology Diabetes and Metabolism Atorvastatin Familial hypercholesterolemia medicine.disease Gastroenterology chemistry.chemical_compound Ezetimibe chemistry Simvastatin Internal medicine medicine Intestinal cholesterol absorption Interstitial glucose lipids (amino acids peptides and proteins) business medicine.drug |
| Zdroj: | Nutrition. 24:613 |
| ISSN: | 0899-9007 |
| DOI: | 10.1016/j.nut.2008.02.015 |
| Popis: | severe familial hypercholesterolemia (FH) with low-density lipoprotein apheresis (LA), selective inhibition of intestinal cholesterol absorption (ezetimibe) and synthesis (statin). Methods: Patient with resistant hypercholesterolemia (n 11, 5 women, 6 men, age 21-60 y, among them patients with homozygous FH n 3) were treated by diet, statin (simvastatin 40 mg or atorvastatin 40-80 mg daily) and LA. Cell-free plasma has been sampled after centrifugation by Cobe-Spectra. LA was performed using a) cascade filtration (filters Evaflux 4A, Kuraray®, n 4) or b) LDL-immunoadsorption (filters Pockard®, n 7). The effect of combined treatment by ezetimibe (Ezetrol® 10 mg daily) was evaluated after 1, 6 and 12 months. Results: Combined treatment with ezetimibe enabled to reach lower serum LDL-cholesterol after each of LA (1,15 0,89 vs 0,81 0,38 mmol/l). Ezetimibe treatment after 12 months combined by LA and statin significantly decreased serum LDL-cholesterol ( 20,6%). Treatment was effective even in two homozygous FH patiens. Two patients did not respond to ezetimibe therapy. Among them, one FH patient was extra cholesterol synthesizer, and a defective response to ezetimebe is supposed in the other FH individual. Conclusion: A combined treatment with ezetimibe and statin should be used in responding patiens with severe hypercholesterolemia treated by LDL-apheresis. Supported by research projects IGA MH CR NR/8497-3, 1A/8689-4, NR/ 8505-3, NR/9103-4. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect